Nadeem Riaz
Auto-generated profile, based on publicly available information

Nadeem Riaz

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RSRobert M Samstein
Robert M Samstein
CLChung-Han Lee
Chung-Han Lee
ASAlexander N. Shoushtari
Alexander N. Shoushtari
MHMatthew D. Hellmann
Matthew D. Hellmann
RSRonglai Shen
Ronglai Shen
LMLuc Morris
Luc Morris

1 November 2017 in Cell
Verified
Journal Article
Closed access
NRNadeem Riaz
Nadeem Riaz
JHJonathan J. Havel
Jonathan J. Havel
VMVladimir Makarov
Vladimir Makarov
ADAlexis Desrichard
Alexis Desrichard
WUWalter J. Urba
Walter J. Urba
TCTimothy A. Chan
Timothy A. Chan

1 November 2017 in Nature
Verified
Journal Article
Closed access
PDF file
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
VBVinod P. Balachandran
Vinod P. Balachandran
MŁMarta Łuksza
Marta Łuksza
JZJulia N. Zhao
Julia N. Zhao
VMVladimir Makarov
Vladimir Makarov
SLSteven D. Leach
Steven D. Leach

2 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
DCDiego Chowell
Diego Chowell
LMLuc Morris
Luc Morris
CGClaud M. Grigg
Claud M. Grigg
JWJeffrey K. Weber
Jeffrey K. Weber
RSRobert M Samstein
Robert M Samstein
TCTimothy A. Chan
Timothy A. Chan
HLA genotype affects response: Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516

20 October 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
RMRajarsi Mandal
Rajarsi Mandal
YŞYasin Şenbabaoğlu
Yasin Şenbabaoğlu
ADAlexis Desrichard
Alexis Desrichard
JHJonathan J. Havel
Jonathan J. Havel
MDMartin Dalin
Martin Dalin
LMLuc Morris
Luc Morris
Recent clinical trials have demonstrated a clear survival advantage in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade. These emerging results reveal that HNSCC is one of the most promising frontiers for immunotherapy research. However, further progress in head and neck immuno-oncology will require a detailed understanding of the immune infiltrative landscape found in these tumors. We leveraged transcriptome data from 280 tumors profiled by The Cancer Genome Atlas (TCGA) to comprehensively characterize the immune landscape of HNSCC in order to develop a rationale for immunotherapeutic strategies in HNSCC and guide clinical investigation. We find that both HPV + and HPV – HNSCC tumors are among the most highly immune-infiltrated cancer types. Strikingly, HNSCC had the highest median Treg/CD8 + T cell ratio and the highest levels of CD56 dim NK cell infiltration, in our pan-cancer analysis of the most immune-infiltrated tumors. CD8 + T cell infiltration and CD56 dim NK cell infiltration each correlated with superior survival in HNSCC. Tumors harboring genetic smoking signatures had lower immune infiltration and were associated with poorer survival, suggesting these patients may benefit from immune agonist therapy. These findings illuminate the immune landscape of HPV + and HPV – HNSCC. Additionally, this landscape provides a potentially novel rationale for investigation of agents targeting modulators of Tregs (e.g., CTLA-4, GITR, ICOS, IDO, and VEGFA) and NK cells (e.g., KIR, TIGIT, and 4-1BB) as adjuncts to anti–PD-1 in the treatment of advanced HNSCC.

1 April 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
BOBrian O’Sullivan
Brian O’Sullivan
SHShao Hui Huang
Shao Hui Huang
JSJie Su
Jie Su
AGAdam S Garden
Adam S Garden
ESErich M Sturgis
Erich M Sturgis
WXWei Xu
Wei Xu